Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

Delayed Quote. Delayed  - 07/29 10:00:00 pm
17.29 USD   +7.39%
07/27 NEKTAR THERAPEU : to Announce Financial Results for the Second Quart..
06/06 NEKTAR THERAPEU : Preclinical Data Presented at ASCO 2016 Annual Mee..
06/03 NEKTAR THERAPEU : ' President and CEO, Howard W. Robin, To Present a..
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Nektar Therapeutics : to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets

share with twitter share with LinkedIn share with facebook
share via e-mail
07/27/2016 | 11:16pm CEST

SAN FRANCISCO, July 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Tuesday, September 6, 2016.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 51021513 (Nektar Therapeutics is the host)

About Nektar
Nektar Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other therapeutic areas. In the area of oncology, Nektar is developing NKTR-214, an immuno-stimulatory CD122-biased agonist, that is in Phase 1/2 clinical development for patients with solid tumors. ONZEALD(TM) (etirinotecan pegol), a long-acting topoisomerase I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and is partnered with Daiichi Sankyo in Europe. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK(TM) (naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in the European Union as MOVENTIG® (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development. In hemophilia, Nektar has a collaboration agreement with Baxalta for ADYNOVATE(TM) [Antihemophilic Factor (Recombinant)], a longer-acting PEGylated Factor VIII therapeutic approved in the U.S. andJapan for patients over 12 with hemophilia A. In anti-infectives, the company has two collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale in Phase 3 for patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK(TM), Baxalta's ADYNOVATE(TM), UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

MOVANTIK(TM) is a trademark and MOVENTIG® is a registered trademark of the AstraZeneca group of companies. ADYNOVATE(TM) is a trademark of Baxalta Inc.

ONZEALD(TM) is a trademark of Nektar Therapeutics.

For Investors and Media:
Jennifer Ruddock of Nektar Therapeutics

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-second-quarter-2016-on-wednesday-august-3-2016-after-close-of-us-based-financial-markets-300305157.html

SOURCE Nektar Therapeutics

share with twitter share with LinkedIn share with facebook
share via e-mail
07/27 NEKTAR THERAPEUTICS : to Announce Financial Results for the Second Quarter 2016 ..
06/27 NEKTAR THERAPEUTICS : Submission of Matters to a Vote of Security Holders (form ..
06/16 NEKTAR THERAPEUTICS : Preclinical Data Presented at ASCO 2016 Annual Meeting Dem..
06/09 NEKTAR THERAPEUTICS : and Daiichi Sankyo Europe GmbH Sign European Licensing Agr..
06/06 NEKTAR THERAPEUTICS : Preclinical Data Presented at ASCO 2016 Annual Meeting Dem..
06/03 NEKTAR THERAPEUTICS : ' President and CEO, Howard W. Robin, To Present at the Je..
06/02 NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
06/02 NEKTAR THERAPEUTICS : Announces Executive Management Promotions
06/02 NEKTAR THERAPEUTICS : Studies from Nektar Therapeutics Further Understanding of ..
06/01 NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement, Regulation FD ..
More news
Sector news : Biotechnology & Medical Research - NEC
02:26pDJMerck Revenue Rises on Cancer, Hepatitis Treatments
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
08:56aDJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12:03p NEKTAR : Does It Finally Have The Midas Touch?
06/03 BIOTECHNOLOGY : Ready To Move Higher - Much Higher
06/01 Nektar Therapeutics inks deal with Daiichi Sankyo for European rights to Onze..
05/03 Nektar Therapeutics' (NKTR) CEO Howard Robin on Q1 2016 Results - Earnings Ca..
05/03 Nektar Therapeutics beats by $0.09, beats on revenue
Financials ($)
Sales 2016 170 M
EBIT 2016 -93,9 M
Net income 2016 -129 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 12,9x
Capi. / Sales 2017 10,4x
Capitalization 2 194 M
More Financials
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 8
Average target price 17,4 $
Spread / Average Target 8,3%
Consensus details
EPS Revisions
More Estimates Revisions
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 724
LONZA GROUP AG12.20%9 855
ALKERMES PLC-39.37%7 276
More Results